Please assess the completion status of the following clinical trial:

Trial Title: MOBILE Study - A Study of Bonviva (Ibandronate) Regimens in Women With Post-Menopausal Osteoporosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* women 55-80 years of age;~* post-menopausal for \>= 5 years;~* ambulatory.~Exclusion Criteria:~* malignant disease diagnosed within the previous 10 years (except basal cell cancer that has been successfully removed);~* breast cancer within the previous 20 years;~* allergy to bisphosphonates;~* previous treatment with an intravenous bisphosphonate at any time;~* previous treatment with an oral bisphosphonate within the last 6 months, \>1 month of treatment within the last year, or \>3 months of treatment within the last 2 years.

- Gender: FEMALE
- Minimum Age: 55 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Ibandronate 2.5 mg (Type: ACTIVE_COMPARATOR): Participants will receive 2.5 milligram (mg) ibandronate Per oral (PO) daily and an oblong placebo tablet PO monthly. Participants will also receive calcium 500 mg /day and vitamin D 400 international units (IU)/day .
- Ibandronate 50/50 mg (Type: EXPERIMENTAL): Participants will receive 100 mg ibandronate PO monthly taken on a single day (2 X 50 mg tablets) and round placebo tablet PO daily. Participants will also receive calcium 500 mg /day and vitamin D 400 IU/day.
- Ibandronate 100 mg (Type: EXPERIMENTAL): Participants will receive 100 mg ibandronate PO monthly divided over two consecutive days (50 mg tablet/day) and a round placebo tablet PO daily. Participants will also receive calcium 500 mg /day and vitamin D 400 IU/day
- Ibandronate 150 mg (Type: EXPERIMENTAL): Participants will receive 150 mg ibandronate PO monthly taken on a single day and a round placebo tablet PO daily. Participants will also receive calcium 500 mg /day and vitamin D 400 IU/day

Based on this trial design, predict the completion outcome and termination type (if applicable).